Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
Beatriz Serrano,Laia Alemany,Sara Tous,Laia Bruni,Gary M. Clifford,Thomas W. Weiss,Francesc Bosch,Silvia de Sanjosé +7 more
TLDR
The addition of HPV 31/33/45/52/58 to HPV types included in current vaccines could prevent almost 90% of ICC cases worldwide and if the nine-valent vaccine achieves the same degree of efficacy than previous vaccines, world incidence rates could be substantially reduced.Abstract:
Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer (ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16/18/31/33/45/52/58) included in an HPV vaccine currently under development. Estimations on ICC were based on an international study of 8,977 HPV positive cases and estimations on precancerous cervical lesions were extracted from a published meta-analysis including 115,789 HPV positive women. Globocan 2008 and 2010 World Population Prospects were used to estimate current and future projections of new ICC cases. RC of the 9 HPV types in ICC was 89.4%, with 18.5% of cases positive for HPV 31/33/45/52/58. Regional variations were observed. RCs varied by histology, ranging between 89.1% in squamous cell carcinomas (SCC) and 95.5% in adenocarcinomas (ADC). HPV 16/18/45 were detected in 94.2% of ADC. RC of the 9 types altogether decreased with age (trend test p < 0.0001), driven by the decrease in older ages of HPV 16/18/45. In contrast, the RC of HPV 31/33/52/58 increased with age. Due to population growth alone, projected estimates of ICC cases attributable to the 9 types are expected to rise from 493,770 new cases in 2012 to 560,887 new cases in 2025. The RCs of individual high risk HPV types varied by cytological and histological grades of HPV-positive precancerous cervical lesions, and there was an under representation of HPV 18 and 45 compared to ICC. The addition of HPV 31/33/45/52/58 to HPV types included in current vaccines could prevent almost 90% of ICC cases worldwide. If the nine-valent vaccine achieves the same degree of efficacy than previous vaccines, world incidence rates could be substantially reduced.read more
Citations
More filters
Journal ArticleDOI
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
Elmar A. Joura,Anna R. Giuliano,Ole Erik Iversen,Céline Bouchard,Constance Mao,Jesper Mehlsen,Edson D. Moreira,Yuen Ngan,Lone Kjeld Petersen,Eduardo Lazcano-Ponce,Punnee Pitisuttithum,Jaime Alberto Restrepo,Gavin Stuart,Linn Woelber,Yuh Cheng Yang,Jack Cuzick,Suzanne M. Garland,Warner K. Huh,Susanne K. Kjaer,Oliver Bautista,Ivan S. F. Chan,Joshua Chen,Richard Gesser,Erin Moeller,Michael Ritter,Scott Vuocolo,Alain Luxembourg +26 more
TL;DR: The 9vHPV vaccine prevented infection and disease related to HPV-31, 33, 45, 52, and 58 in a susceptible population and generated an antibody response to HPV -6, 11, 16, and 18 that was noninferior to that generated by the qHPV Vaccine.
Journal Article
Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
Emiko Petrosky,Joseph A. Bocchini,Susan Hariri,Harrell W. Chesson,C. Robinette Curtis,Mona Saraiya,Elizabeth R. Unger,Lauri E. Markowitz +7 more
TL;DR: Evidence considered by ACIP in recommending 9vHPV as one of three HPV vaccines that can be used for vaccination is summarized and recommendations for vaccine use are provided.
Journal ArticleDOI
Global Cancer in Women: Burden and Trends
TL;DR: The burden of cancer among women could be substantially reduced in both HICs and LMICs through broad and equitable implementation of effective interventions, including tobacco control, HPV and HBV vaccination, and screening (breast, cervix, and colorectum).
Journal ArticleDOI
US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
Mona Saraiya,Elizabeth R. Unger,Trevor D. Thompson,Charles F. Lynch,Brenda Y. Hernandez,Christopher Lyu,Martin Steinau,Meg Watson,Edward J. Wilkinson,Claudia Hopenhayn,Glenn Copeland,Wendy Cozen,Edward S. Peters,Youjie Huang,Maria Sibug Saber,Sean F. Altekruse,Marc T. Goodman +16 more
TL;DR: In the United States, current vaccines will reduce most HPV-associated cancers; a smaller additional reduction would be contributed by the new 9-valent vaccine.
Journal ArticleDOI
Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience
Suzanne M. Garland,Susanne K. Kjaer,Nubia Muñoz,Stan L. Block,Darron R. Brown,Mark J. DiNubile,Brianna Lindsay,Barbara J. Kuter,Gonzalo Perez,Géraldine Dominiak-Felden,Alfred J. Saah,Rosybel Drury,Rituparna Das,Christine Velicer +13 more
TL;DR: Substantial reductions in HPV 6/11/16/18 infection, anogenital warts, and cervical lesions have been achieved.
References
More filters
Journal ArticleDOI
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
TL;DR: The results for 20 world regions are presented, summarizing the global patterns for the eight most common cancers, and striking differences in the patterns of cancer from region to region are observed.
Journal ArticleDOI
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
Jan M. M. Walboomers,M. V. Jacobs,M. M. Manos,Franz X. Bosch,J. A. Kummer,Keerti V. Shah,Peter J.F. Snijders,Julian Peto,Chris J.L.M. Meijer,Nubia Muñoz +9 more
TL;DR: The presence of HPV in virtually all cervical cancers implies the highest worldwide attributable fraction so far reported for a specific cause of any major human cancer, and the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening.
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]
J Ferlay,I Soerjomataram,M Ervik,R Dikshit,S Eser,Colin Mathers,M Rebelo,D.M. Parkin,David Forman,Freddie Bray,S Elser,M Ervick,Donald Maxwell Parkin +12 more
Journal ArticleDOI
Human papillomavirus and cervical cancer
TL;DR: The new HPV-oriented model of cervical carcinogenesis should gradually replace older morphological models based only on cytology and histology, and can minimise the incidence of cervical cancer, and the morbidity and mortality it causes, even in low-resource settings.
Journal ArticleDOI
Human Papillomavirus and Cervical Cancer
TL;DR: Currently, the clearest role for HPV DNA testing is to improve diagnostic accuracy and limit unnecessary colposcopy in patients with borderline or mildly abnormal cytologic test results.
Related Papers (5)
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Silvia de Sanjosé,Wim Quint,Laia Alemany,D.T. Geraets,Jo Ellen Klaustermeier,Belen Lloveras,Sara Tous,Ana Félix,Luis Eduardo Bravo,Hai Rim Shin,Carlos S. Vallejos,Patricia Alonso de Ruiz,Marcus Aurelho Lima,Núria Guimerà,Omar Clavero,Maria Alejo,Antonio Llombart-Bosch,Chou Cheng-Yang,Silvio Tatti,Elena Kasamatsu,Ermina Iljazovic,Michael Odida,Rodrigo Prado,Muhieddine Seoud,Magdalena Grce,Alp Usubutun,Asha Jain,Gustavo Adolfo Hernandez Suarez,Luis Estuardo Lombardi,Aekunbiola Banjo,Clara Menendez,Efren J. Domingo,Julio Velasco,Ashrafun Nessa,Saibua Chichareon,You-Lin Qiao,Enrique Lerma,Suzanne M. Garland,Toshiyuki Sasagawa,Annabelle Ferrera,Doudja Hammouda,Luciano Mariani,Adela Pelayo,Ivo Šteiner,Esther Oliva,Chris J. L. M. Meijer,Waleed Al-Jassar,Eugenia Cruz,Thomas C. Wright,Ana Puras,Cecilia L. Llave,Maria Tzardi,Theodoros Agorastos,Victoria Garcia-Barriola,Christine Clavel,Jaume Ordi,Miguel Andújar,Xavier Castellsagué,Gloria I. Sanchez,Andrzej Nowakowski,Jacob Bornstein,Nubia Muñoz,F. Xavier Bosch +62 more
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
Elmar A. Joura,Anna R. Giuliano,Ole Erik Iversen,Céline Bouchard,Constance Mao,Jesper Mehlsen,Edson D. Moreira,Yuen Ngan,Lone Kjeld Petersen,Eduardo Lazcano-Ponce,Punnee Pitisuttithum,Jaime Alberto Restrepo,Gavin Stuart,Linn Woelber,Yuh Cheng Yang,Jack Cuzick,Suzanne M. Garland,Warner K. Huh,Susanne K. Kjaer,Oliver Bautista,Ivan S. F. Chan,Joshua Chen,Richard Gesser,Erin Moeller,Michael Ritter,Scott Vuocolo,Alain Luxembourg +26 more
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Suzanne M. Garland,Suzanne M. Garland,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Diane M. Harper,Sepp Leodolter,Grace W.K. Tang,Daron G. Ferris,Marc Steben,Janine T. Bryan,Frank J. Taddeo,Radha Railkar,Mark T. Esser,Heather L. Sings,Micki Nelson,John W. Boslego,Carlos Sattler,Eliav Barr,Laura A. Koutsky +19 more